Cargando…

Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes

BACKGROUND: The greatest challenges in vaccine development include optimization of DNA vaccines for use in humans, creation of effective single-dose vaccines, development of delivery systems that do not involve live viruses, and the identification of effective new adjuvants. Herein, we describe a no...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosada, Rogério S, Torre, Lucimara Gaziola de la, Frantz, Fabiani G, Trombone, Ana PF, Zárate-Bladés, Carlos R, Fonseca, Denise M, Souza, Patrícia RM, Brandão, Izaíra T, Masson, Ana P, Soares, Édson G, Ramos, Simone G, Faccioli, Lúcia H, Silva, Célio L, Santana, Maria HA, Coelho-Castelo, Arlete AM
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2500095/
https://www.ncbi.nlm.nih.gov/pubmed/18647414
http://dx.doi.org/10.1186/1471-2172-9-38
_version_ 1782158296807899136
author Rosada, Rogério S
Torre, Lucimara Gaziola de la
Frantz, Fabiani G
Trombone, Ana PF
Zárate-Bladés, Carlos R
Fonseca, Denise M
Souza, Patrícia RM
Brandão, Izaíra T
Masson, Ana P
Soares, Édson G
Ramos, Simone G
Faccioli, Lúcia H
Silva, Célio L
Santana, Maria HA
Coelho-Castelo, Arlete AM
author_facet Rosada, Rogério S
Torre, Lucimara Gaziola de la
Frantz, Fabiani G
Trombone, Ana PF
Zárate-Bladés, Carlos R
Fonseca, Denise M
Souza, Patrícia RM
Brandão, Izaíra T
Masson, Ana P
Soares, Édson G
Ramos, Simone G
Faccioli, Lúcia H
Silva, Célio L
Santana, Maria HA
Coelho-Castelo, Arlete AM
author_sort Rosada, Rogério S
collection PubMed
description BACKGROUND: The greatest challenges in vaccine development include optimization of DNA vaccines for use in humans, creation of effective single-dose vaccines, development of delivery systems that do not involve live viruses, and the identification of effective new adjuvants. Herein, we describe a novel, simple technique for efficiently vaccinating mice against tuberculosis (TB). Our technique consists of a single-dose, genetic vaccine formulation of DNA-hsp65 complexed with cationic liposomes and administered intranasally. RESULTS: We developed a novel and non-toxic formulation of cationic liposomes, in which the DNA-hsp65 vaccine was entrapped (ENTR-hsp65) or complexed (COMP-hsp65), and used to immunize mice by intramuscular or intranasal routes. Although both liposome formulations induced a typical Th1 pattern of immune response, the intramuscular route of delivery did not reduce the number of bacilli. However, a single intranasal immunization with COMP-hsp65, carrying as few as 25 μg of plasmid DNA, leads to a remarkable reduction of the amount of bacilli in lungs. These effects were accompanied by increasing levels of IFN-γ and lung parenchyma preservation, results similar to those found in mice vaccinated intramuscularly four times with naked DNA-hsp65 (total of 400 μg). CONCLUSION: Our objective was to overcome the significant obstacles currently facing DNA vaccine development. Our results in the mouse TB model showed that a single intranasal dose of COMP-hsp65 elicited a cellular immune response that was as strong as that induced by four intramuscular doses of naked-DNA. This formulation allowed a 16-fold reduction in the amount of DNA administered. Moreover, we demonstrated that this vaccine is safe, biocompatible, stable, and easily manufactured at a low cost. We believe that this strategy can be applied to human vaccines to TB in a single dose or in prime-boost protocols, leading to a tremendous impact on the control of this infectious disease.
format Text
id pubmed-2500095
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25000952008-08-08 Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes Rosada, Rogério S Torre, Lucimara Gaziola de la Frantz, Fabiani G Trombone, Ana PF Zárate-Bladés, Carlos R Fonseca, Denise M Souza, Patrícia RM Brandão, Izaíra T Masson, Ana P Soares, Édson G Ramos, Simone G Faccioli, Lúcia H Silva, Célio L Santana, Maria HA Coelho-Castelo, Arlete AM BMC Immunol Research Article BACKGROUND: The greatest challenges in vaccine development include optimization of DNA vaccines for use in humans, creation of effective single-dose vaccines, development of delivery systems that do not involve live viruses, and the identification of effective new adjuvants. Herein, we describe a novel, simple technique for efficiently vaccinating mice against tuberculosis (TB). Our technique consists of a single-dose, genetic vaccine formulation of DNA-hsp65 complexed with cationic liposomes and administered intranasally. RESULTS: We developed a novel and non-toxic formulation of cationic liposomes, in which the DNA-hsp65 vaccine was entrapped (ENTR-hsp65) or complexed (COMP-hsp65), and used to immunize mice by intramuscular or intranasal routes. Although both liposome formulations induced a typical Th1 pattern of immune response, the intramuscular route of delivery did not reduce the number of bacilli. However, a single intranasal immunization with COMP-hsp65, carrying as few as 25 μg of plasmid DNA, leads to a remarkable reduction of the amount of bacilli in lungs. These effects were accompanied by increasing levels of IFN-γ and lung parenchyma preservation, results similar to those found in mice vaccinated intramuscularly four times with naked DNA-hsp65 (total of 400 μg). CONCLUSION: Our objective was to overcome the significant obstacles currently facing DNA vaccine development. Our results in the mouse TB model showed that a single intranasal dose of COMP-hsp65 elicited a cellular immune response that was as strong as that induced by four intramuscular doses of naked-DNA. This formulation allowed a 16-fold reduction in the amount of DNA administered. Moreover, we demonstrated that this vaccine is safe, biocompatible, stable, and easily manufactured at a low cost. We believe that this strategy can be applied to human vaccines to TB in a single dose or in prime-boost protocols, leading to a tremendous impact on the control of this infectious disease. BioMed Central 2008-07-22 /pmc/articles/PMC2500095/ /pubmed/18647414 http://dx.doi.org/10.1186/1471-2172-9-38 Text en Copyright © 2008 Rosada et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Rosada, Rogério S
Torre, Lucimara Gaziola de la
Frantz, Fabiani G
Trombone, Ana PF
Zárate-Bladés, Carlos R
Fonseca, Denise M
Souza, Patrícia RM
Brandão, Izaíra T
Masson, Ana P
Soares, Édson G
Ramos, Simone G
Faccioli, Lúcia H
Silva, Célio L
Santana, Maria HA
Coelho-Castelo, Arlete AM
Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes
title Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes
title_full Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes
title_fullStr Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes
title_full_unstemmed Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes
title_short Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes
title_sort protection against tuberculosis by a single intranasal administration of dna-hsp65 vaccine complexed with cationic liposomes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2500095/
https://www.ncbi.nlm.nih.gov/pubmed/18647414
http://dx.doi.org/10.1186/1471-2172-9-38
work_keys_str_mv AT rosadarogerios protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes
AT torrelucimaragazioladela protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes
AT frantzfabianig protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes
AT tromboneanapf protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes
AT zaratebladescarlosr protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes
AT fonsecadenisem protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes
AT souzapatriciarm protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes
AT brandaoizairat protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes
AT massonanap protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes
AT soaresedsong protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes
AT ramossimoneg protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes
AT faccioliluciah protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes
AT silvaceliol protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes
AT santanamariaha protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes
AT coelhocasteloarleteam protectionagainsttuberculosisbyasingleintranasaladministrationofdnahsp65vaccinecomplexedwithcationicliposomes